Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval

Expert Opinion on Drug Safety

Volumn 1, Issue 2, 2002, Pages 121-128

  Iannini, Paul B ^a  

^a DANBURY HOSPITAL   (United States)

Author keywords

cardiac toxicity; QTc prolongation; Torsades de Pointes; ventricular arrhythmia

Indexed keywords

ANTIINFECTIVE AGENT; MACROLIDE; QUINOLONE DERIVATIVE; VOLTAGE GATED POTASSIUM CHANNEL;

CHEMICALLY INDUCED DISORDER; DRUG EFFECT; ELECTROCARDIOGRAPHY; EXPERT WITNESS; FEMALE; HEART VENTRICLE FIBRILLATION; HUMAN; LONG QT SYNDROME; MALE; REVIEW; RISK FACTOR; TORSADE DES POINTES;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ELECTROCARDIOGRAPHY; EXPERT TESTIMONY; FEMALE; FLUOROQUINOLONES; HUMANS; LONG QT SYNDROME; MACROLIDES; MALE; POTASSIUM CHANNELS, VOLTAGE-GATED; RISK FACTORS; TORSADES DE POINTES; VENTRICULAR FIBRILLATION;

EID: 0043237932     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.1.2.121     Document Type: Review

References (15)

1. OWENS RC JR: Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes. Pharmacotherapy (2001) 21:301-309.
2. BRANDWISS MW, RICHARDSON WS, BAROLD SS: Erythromycin-induced QT prolongation and polymorphic ventricular tachycardia (torsades de pointes): case report and review. Clin. Infect. Dis. (1994) 18:995-998. (Pubitemid 24171352)
3. GRANBERRY MC, GARDNER SF: Erythromycin monotherapy associated with torsades de pointes. Ann. Pharmacother. 30(1):77-78.
4. TSICHIDA SJ, GUAY DR, STRAKA RJ, HOEY LL, JOHANNING R, VANCEBRYAN K: QTc-interval prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: a prospective evaluation and review of the literature. Pharmacotherapy (1996) 16:663-674. (Pubitemid 26285920)
5. LEE KL, JIM MH, TANG SC, TAI YT: QT prolongation and Torsades de Pointes associated with clarithromycin. Am. J. Med. (1998) 104(4):395-396. (Pubitemid 28211031)
6. HAYASHI Y, IKEDA U, HASHIMOTO T, WANTANABE T, MITSUHASHI T, SHIMADA K: Torsades de Pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia. Pacing Clin. Electrophysiol. (1999) 22:672-674. (Pubitemid 29222086)
7. IANNINI PB, CIRCIUMARU I, BYAZROVA E, KRAMER H: QTc prolongation associated with levofloxacin. Br. Med. J. (2001) 7277:46-47. Letter.
8. SAMANTHA F: QTc interval prolongation and polymorphic ventricular tachycardia associated with levofloxacin. Am. J. Med. (1999) 107:528-529.
9. DUPONT H, TIMSIT JF, SOUWEINE B, GACHOT B, WOLFF M, REGNIER B: Torsades de Pointes probably related to sparfloxacin. Eur. J. Clin. Micrbiol. Infect. Dis. (1996) 15(4):350-351.
10. IANNINI PB, CIRCIUMARU I: Gatifloxacin-induced QTc prolongation and ventricular tachycardia. Pharmacotherapy (2001) 21:361-362. (Pubitemid 32208852)
11. BERTINO JS, OWENS RC JR, CARNES CD, IANNINI PB: Gatifloxacin associated corrected QT interval prolongation, Torsades de Pointes, and ventricular fibrillation in patients with known risk factors. Clin. Infect. Dis. (2002) 34:861-863. (Pubitemid 34194860)
12. FROTHINGHAM R: Rates of Torsades de Pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin and moxifloxacin. Pharmacotherapy (2001) 21:1468-1472. (Pubitemid 33117251)
13. IANNINI PB, TILLOTSON GS: Evaluating the risk of cardiac toxicity. Pharmacotherapy (2001) 21:261-262. Editorial.
14. + channels and their role in cardiac arrhythmias. Am. J. Med. (2001) 110:50-59. (Pubitemid 32056328)
15. BEERMAN B: SMPA (Swedish Medical Products Agency) (December 1999).